IR BioSciences Holdings, Inc. is a development-stage biotechnology company. The Company, through its wholly owned subsidiary, ImmuneRegen BioSciences, Inc. (ImmuneRegen), is engaged in the research and development of the drug candidate Homspera for use in therapies in pulmonology, immunology and hematology. The Company focuses on the research and development of therapies in the areas of pulmonary fibrosis, influenza infection and radiation-induced Neutropenia. Other areas of research include vaccine adjuvant activity evinced against certain forms of cancer and applications for wound healing and for regenerating or strengthening the human immune system, in part, through stimulating human adult stem cells.